Latest Options News

Visionflex Group Limited reported a mixed quarter with a modest cash burn but strengthened its balance sheet through a significant debt-to-equity conversion and maintained solid funding capacity.

Mayfield Group Holdings has acquired a strategic industrial property adjacent to its BE Switchcraft operations, enabling operational synergies and capacity expansion to support a $30 million contract pipeline.

Anteris Technologies has closed a $320 million capital raise, combining a $230 million public offering and a strategic private placement with Medtronic, to advance its DurAVR heart valve clinical trials and manufacturing growth.

Celsius Resources has released a Definitive Feasibility Study for its Maalinao-Caigutan-Biyog (MCB) Copper-Gold Project, confirming robust economics and a 35-year mine life. The study highlights strong returns, low operating costs, and a clear path to development in the Philippines.

Accelerate Resources has advanced its gold exploration at Balagundi and manganese prospects in Pilbara, bolstered by a $900,000 capital raise and a strategic joint venture at the Comet Gold Project.

Anteris Technologies Global Corp. has entered a material definitive agreement to raise approximately $320 million through a public offering and a strategic private placement with Medtronic’s subsidiary. The capital will support clinical trials and manufacturing expansion for its innovative heart valve technology.

Falcon Metals has reported compelling high-grade gold results from its Blue Moon project in Victoria, extending mineralisation along strike and confirming the potential for a significant new gold reef. The company also advances exploration at Pyramid Hill and Errabiddy while maintaining a strong cash position.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

Arovella Therapeutics has filed an IND application for its lead CAR-iNKT therapy ALA-101, selected a CRO for its upcoming phase 1 trial, and secured $19.4 million in cash to fund clinical progress and pipeline expansion.

Venus Metals Corporation progresses its Sandstone Bellchambers gold project with a new mining lease and exploration targets, while extending its Bridgetown JV farm-in and navigating an unsolicited takeover offer.

Dalaroo Metals is fast-tracking its 2026 exploration program at the Blue Lagoon project in Greenland following promising 2025 results that confirmed widespread rare earth and critical mineralisation. The company aims to define drill-ready targets and advance its position in the strategic critical minerals sector.